If you have been reading about salt form and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-09. Numbers and descriptions here follow the published literature rather than marketing material.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material may be hygroscopic |
| Solubility class | Soluble in water, DMSO and DMF | Dilution into aqueous buffer can cause precipitation |
| Storage of solid | Minus 20 degrees C, desiccated, dark | Aliquot to limit repeated opening of the vial |
| Storage of solution | Minus 20 to minus 80 degrees C, aliquoted | Avoid repeated freeze-thaw cycles |
| Identity method | Reversed-phase HPLC with mass spectrometry | Retention time and mass are checked together |
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Several hypotheses have been proposed for how bone evolved as a structural element in vertebrates. One hypothesis is that bone developed from tissues that evolved to store minerals. Specifically, calcium-based minerals were stored in cartilage and bone was an exaptation development from this calcified cartilage. However, other possibilities include bony tissue evolving as an osmotic barrier, or as a protective structure.
=== Harmful chemicals === Researchers have detected many PFCs in microwave popcorn bags used as coating materials for oil and moisture resistance. The amount of PFOA in some microwave popcorn bags is determined as high as 300 μg kg−1. Besides PFOA and PFOS, Moral et al. also determined other perfluorocarboxylic acids (PFCAs) in popcorn packaging, including perfluoroheptanoic (PFHpA), perfluorononanoic (PFNA), perfluorodecanoic (PFDA), perfluoroundecanoic (PFUnA), and perfluorododecanoic (PFDoA) acids. Due to the toxicity of PFOA, major U.S. manufacturers volunteered to phase out production of PFOA by the end of 2015. In addition, the use of perfluoroalkyl ethyl-containing food-contact substances are no longer allowed by the U.S Food and Drug Administration (FDA) regulations in January 2016. However, although the production of PFOA and PFOS was reduced, the production of fluorotelomer-based chemicals applied to food contact papers is still increasing. Some compounds, such as polyfluoroalkyl phosphate surfactants (PAPs) or fluorotelomers (FTOH), have been used in some brands of microwave popcorn bags. Those compounds are precursors of PFCAs, and evidence shows that they are more toxic than PFCAs themselves. Furthermore, they may also be degraded to PFCAs, and therefore leading to the increase of PFCAs concentrations in the environment and generating adverse effects.
=== Brain nonsynaptic glutamatergic signaling circuits === Extracellular glutamate in Drosophila brains has been found to regulate postsynaptic glutamate receptor clustering, via a process involving receptor desensitization. A gene expressed in glial cells actively transports glutamate into the extracellular space, while, in the nucleus accumbens-stimulating group II metabotropic glutamate receptors, this gene was found to reduce extracellular glutamate levels. This raises the possibility that this extracellular glutamate plays an "endocrine-like" role as part of a larger homeostatic system.
== History == The founding of the Jere Ngoni Kingdom was precipitated by the Mfecane, a period of widespread instability and state formation in Southern Africa, caused by pre-existing trends of political centralisation which were catalysed by the effects of international trade, environmental instability, and European colonial expansion. An early state was the Ndwandwe led by Zwide; after Zwide defeated Dingiswayo's Mthethwa c. 1816, the Mthethwa state disintegrated and some groups were incorporated into Ndwandwe. Zwide next engaged the expanding Zulu led by Shaka, but was defeated in battle c. 1819. Following this defeat, Zwangendaba (one of Ndwandwe's Indunas) led his group on a long-distance migration northwards, and they became known as the Jere Ngoni (separate from the Maseko Ngoni). Zwangendaba initially settled around the Mkomati River (north of Delagoa Bay), but fled north after clashing with other rulers such as Soshangane, Nxaba, and Mzilikazi. Zwangendaba entered onto the Zimbabwean Plateau and raided the Rozvi Empire for several years, before crossing the Zambezi in 1835. He left some troops behind with a relative of his (Nyamazana) who later killed the Rozvi king. In 1840 Zwangendaba's forces massacred many Tonga for allegedly causing him illness, and they captured many Chewa and Tumbuka. The Ngoni later reached the Ufipa Plateau, where in the late 1840s Zwangendaba died.
Sources: en.wikipedia.org
=== Metabolic and covalent labeling of glycans === Metabolic labeling of glycans can be used as a way to detect glycan structures. A well known strategy involves the use of azide-labeled sugars which can be reacted using the Staudinger ligation. This method has been used for in vitro and in vivo imaging of glycans.
== Reaction mechanism == The nucleophilic attack on the carbonyl group proceeds via the Bürgi-Dunitz trajectory. The angle between the line of nucleophilic attack and the C-O bond is greater than 90˚ due to a better orbital overlap between the HOMO of the nucleophile and the π* LUMO of the C-O double bond.
{\displaystyle {\begin{aligned}u_{x}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kx-{\frac {\pi }{3}}\right)\cos \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)-\cos \left(kz-{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{y}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(ky-{\frac {\pi }{3}}\right)\cos \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)-\cos \left(kx-{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\\u_{z}&={\frac {4{\sqrt {2}}}{3{\sqrt {3}}}}\,U_{0}\left[\,\sin \left(kz-{\frac {\pi }{3}}\right)\cos \left(kx+{\frac {\pi }{3}}\right)\sin \left(ky+{\frac {\pi }{2}}\right)-\cos \left(ky-{\frac {\pi }{3}}\right)\sin \left(kz+{\frac {\pi }{3}}\right)\sin \left(kx+{\frac {\pi }{2}}\right)\,\right]e^{-3\nu k^{2}t}\end{aligned}}}
Sources: en.wikipedia.org
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.
Peptides are commonly isolated as acetate or trifluoroacetate salts, and the counterion contributes to total mass. Two vials with identical peptide content can therefore differ in weight and in measured response. Residual trifluoroacetate is also relevant in cell-based work because it can influence membrane behaviour.
Degradation products are often closely related to the parent molecule, making them hard to resolve with a single method. Counterion variability adds a further source of scatter between laboratories. Because no pharmacopoeial monograph exists for melanotan-2, groups rely on method-specific validation rather than a shared reference standard.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.